Evidence map›Paper›PMID 29985265›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2018

Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068.

Yinfeng Zhang, Mariya V Sivay, Sarah E Hudelson, William Clarke, Autumn Breaud, Jing Wang, Estelle Piwowar-Manning, Yaw Agyei, Jessica M Fogel, Erica L Hamilton and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Yinfeng ZhangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Mariya V SivayDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Sarah E HudelsonDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
William ClarkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Autumn BreaudDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Jing WangStatistical Center for HIV/AIDS Research & Prevention (SCHARP), Seattle, WA.
Estelle Piwowar-ManningDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Yaw AgyeiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Jessica M FogelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Erica L HamiltonScience Facilitation Department, FHI 360, Durham, NC.
Amanda SelinCarolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Catherine MacPhailSchool of Health and Society, University of Wollongong, Australia.
Kathleen KahnMRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Francesc Xavier Gómez-OlivéMRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
James P HughesDepartment of Biostatistics, University of Washington, Seattle, WA.
Audrey PettiforMRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Johns Hopkins University · USJohns Hopkins Medicine · USAgincourt Health and Socio-Demographic Surveillance System · ZAUniversity of North Carolina at Chapel Hill · USCancer Research And Biostatistics · USFamily Health International 360 · USUniversity of Washington · USUniversity of Wollongong · AU

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Effects of Cash Transfer and Community Mobilization in Young South African WomenR01MH087118 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PETTIFOR, AUDREY · 2009 to 2013
$2.5M
NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069423NICHD NIH HHS P2C HD050924NIMH NIH HHS R01 MH087118
6 · The paper itself

Abstract

backgroundAntiretroviral (ARV) drugs are used for HIV treatment and prevention. We analyzed ARV drug use and HIV drug resistance in a cohort of young women in rural South Africa enrolled in the HIV Prevention Trials Network (HPTN) 068 study, which evaluated the use of a cash transfer conditional on school attendance to reduce HIV incidence.

methodsARV drug testing was performed using plasma samples from 2526 young women. This included 2526 enrollment samples (80 HIV-infected and 2446 HIV-uninfected) and 162 seroconversion samples (first HIV-positive study visit). Testing was performed using a qualitative assay that detects 20 ARV drugs from 5 drug classes. HIV drug resistance testing was performed with the ViroSeq HIV-1 Genotyping System for samples that had HIV viral loads ≥400 copies per milliliter.

resultsAt enrollment, ARV drugs were detected in 10 (12.5%) of 80 HIV-infected young women. None of 2446 HIV-uninfected young women had ARV drugs detected at enrollment. ARV drugs were also detected in 16 (9.9%) of 162 seroconverters. At enrollment, 9 (13.4%) of 67 young women with genotyping results had HIV drug resistance; resistance was also detected in 9 (6.9%) of 131 seroconverters with genotyping results.

conclusionsMost of the HIV-infected young women in this cohort from rural South Africa were not taking ARV drugs, suggesting they were unaware of their HIV status or were not in care. HIV drug resistance was detected in young women with both prevalent and new HIV infection.

Indexed as

Drug Resistance, ViralAdolescentAnti-HIV AgentsDrug UtilizationFemaleGenotypeGenotyping TechniquesHIV-1HIV InfectionsHumansIncidencePlasmaRural PopulationSouth AfricaViral LoadYoung AdultAnti-HIV Agents

Identifiers

PMID29985265
PMCPMC6185777
OpenAlexW2859985921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.